In 2008, Susan G. Komen for the Cure awarded a Promise Grant to a group of researchers to further study tamoxifen and its correlation between hot flashes and the CYP2D6 gene. Researchers proved that differences in CYP2D6 did not predict who would or would not benefit from taking tamoxifen. They did this by analyzing the DNA of breast cancer tumors from women who had received tamoxifen. In addition, they proved that hot flashes did not correlate to differences in CYP2D6.
This research result is important because it will prevent women and their doctors from making a treatment decision based on erroneous information and also prevent doctors from ordering expensive, unnecessary tests. In addition, this research study highlights the importance of clinical trials and tissue banking. Breast cancer patients participated in a large treatment trial and agreed to let the researchers collect tissue from their breast cancer tumors. Without this, scientists would not have been able to analyze the tumors and compare their findings with treatment outcomes for these women. This kind of research needs to be supported because they will help realize the promise of personalized medicine. Read more on this here.